Boileau C - Deforges S - Peret A - Scavarda D - Bartolomei F - Giles A - Partouche N - Gautron J - Viotti J - Janowitz H - Penchet G - Marchal C - Lagarde S - Trebuchon A - Villeneuve N - Rumi J - Marissal T - Khazipov R - Khalilov I - Martineau F - Maréchal M - Lepine A - Milh M - Figarella-Branger D - Dougy E - Tong S - Appay R - Baudouin S - Mercer A - Smith JB - Danos O - Porter R - Mulle C - Crépel V
Annals of neurology
Temporal lobe epilepsy (TLE) is characterized by recurrent seizures generated in the limbic system, particularly in the hippocampus. In TLE, recurrent mossy fiber sprouting from dentate gyrus granule cells (DGCs) crea an aberrant epileptogenic network between DGCs which operates via ectopically expressed GluK2/GluK5-containing kainate receptors (KARs). TLE patients are often resistant to anti-seizure medications and suffer significant comorbidities; hence, there is an urgent need for novel therapies. Previously, we have shown that GluK2 knockout mice are protected from seizures. This study aims at providing evidence that downregulating KARs in the hippocampus using gene therapy reduces chronic epileptic discharges in TLE.